Regenxbio Inc (RGNX)

Dec 21, 2024

Stifel Financial Corp Boosts Position in REGENXBIO Inc. (NASDAQ:RGNX) - Defense World

Dec 21, 2024

Dec 20, 2024

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Sells 4,880 Shares of REGENXBIO Inc. (NASDAQ:RGNX) - Defense World

Dec 20, 2024

Dec 19, 2024

REGENXBIO to Participate in Upcoming Investor Conferences - Kilgore News Herald

Dec 19, 2024

Dec 17, 2024

BNP Paribas Financial Markets Purchases 17,533 Shares of REGENXBIO Inc. (NASDAQ:RGNX) - Defense World

Dec 17, 2024

Dec 16, 2024

Trading (RGNX) With Integrated Risk Controls - Stock Traders Daily

Dec 16, 2024

Dec 16, 2024

REGENXBIO: A Hidden Gem in Gene Therapy with Promising Pipeline and Growth Potential - mediahousepress

Dec 16, 2024

Dec 16, 2024

REGENXBIO's SWOT analysis: gene therapy firm's stock poised for growth By Investing.com - Investing.com Australia

Dec 16, 2024

Dec 16, 2024

REGENXBIO's SWOT analysis: gene therapy firm's stock poised for growth - Investing.com India

Dec 16, 2024

Dec 15, 2024

National Bank of Canada FI Invests $713,000 in REGENXBIO Inc. (NASDAQ:RGNX) - MarketBeat

Dec 15, 2024

Dec 14, 2024

Regenxbio stock hits 52-week low at $8.39 amid market challenges - Investing.com Australia

Dec 14, 2024

Dec 14, 2024

REGENXBIO Inc. (NASDAQ:RGNX) Shares Bought by Charles Schwab Investment Management Inc. - Defense World

Dec 14, 2024

Dec 13, 2024

Royal Bank of Canada Reiterates “Outperform” Rating for REGENXBIO (NASDAQ:RGNX) - Defense World

Dec 13, 2024

Dec 12, 2024

REGENXBIO Inc. (NASDAQ:RGNX) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat

Dec 12, 2024

Dec 12, 2024

REGENXBIO Inc. (NASDAQ:RGNX) Given Consensus Rating of “Moderate Buy” by Analysts - Defense World

Dec 12, 2024

Dec 11, 2024

Where Regenxbio Stands With Analysts - Benzinga

Dec 11, 2024

Dec 09, 2024

Jacobs Levy Equity Management Inc. Trims Position in REGENXBIO Inc. (NASDAQ:RGNX) - MarketBeat

Dec 09, 2024

Dec 08, 2024

REGENXBIO to Host Conference Call on November 6 to Discuss Third Quarter 2024 Financial Results and Recent Operational Highlights - The Eastern Progress Online

Dec 08, 2024

Dec 06, 2024

REGENXBIO Announces Positive Data from Pivotal Dose Level of RGX-121 Demonstrating Long-Term Systemic Effect - The Eastern Progress Online

Dec 06, 2024

Dec 06, 2024

Regenxbio stock touches 52-week low at $8.51 amid market challenges - Investing.com Canada

Dec 06, 2024

Dec 06, 2024

(RGNX) Trading Report - Stock Traders Daily

Dec 06, 2024

Dec 06, 2024

Regenxbio Updates Leadership, Names New CEO - Contract Pharma

Dec 06, 2024

Dec 05, 2024

REGENXBIO Inc. (NASDAQ:RGNX) is Redmile Group LLC's 10th Largest Position - MarketBeat

Dec 05, 2024

Nov 29, 2024

Connor Clark & Lunn Investment Management Ltd. Makes New Investment in REGENXBIO Inc. (NASDAQ:RGNX) - MarketBeat

Nov 29, 2024

Nov 26, 2024

REGENXBIO's SWOT analysis: gene therapy stock poised for growth amid challenges - Investing.com India

Nov 26, 2024

Nov 25, 2024

How To Trade (RGNX) - Stock Traders Daily

Nov 25, 2024

Nov 25, 2024

HC Wainwright Cuts REGENXBIO (NASDAQ:RGNX) Price Target to $36.00 - Defense World

Nov 25, 2024

Nov 24, 2024

REGENXBIO (NASDAQ:RGNX) Given Buy Rating at Chardan Capital - Defense World

Nov 24, 2024

Nov 23, 2024

Regenxbio price target lowered to $36 from $40 at H.C. Wainwright - MSN

Nov 23, 2024

Nov 21, 2024

HC Wainwright Has Lowered Expectations for REGENXBIO (NASDAQ:RGNX) Stock Price - MarketBeat

Nov 21, 2024

Nov 21, 2024

Regenxbio starts pivotal trial testing DMD gene therapy RGX-202 - Muscular Dystrophy News

Nov 21, 2024

Nov 21, 2024

Leerink Partnrs Increases Earnings Estimates for REGENXBIO - MarketBeat

Nov 21, 2024

Nov 21, 2024

H.C. Wainwright sees 45% approval probability for RGX-202, reiterates Buy on Regenxbio stock - Investing.com Nigeria

Nov 21, 2024

Nov 21, 2024

H.C. Wainwright sees 45% approval probability for RGX-202, reiterates Buy on Regenxbio stock By Investing.com - Investing.com South Africa

Nov 21, 2024

Nov 20, 2024

Chardan Capital Reaffirms Buy Rating for REGENXBIO (NASDAQ:RGNX) - MarketBeat

Nov 20, 2024

Nov 20, 2024

Regenxbio down 13% ahead of data readout for muscular dystrophy asset - MSN

Nov 20, 2024

Nov 20, 2024

Regenxbio surges 10% as it launches pivotal phase of muscular dystrophy asset trial - MSN

Nov 20, 2024

Nov 19, 2024

Regenxbio eyes 2026 filing for Duchenne muscular dystrophy gene therapy - Pharmaceutical Technology

Nov 19, 2024

Nov 19, 2024

US Bancorp DE Has $26,000 Stake in REGENXBIO Inc. (NASDAQ:RGNX) - Defense World

Nov 19, 2024

Nov 19, 2024

Morgan Stanley Reiterates “Overweight” Rating for REGENXBIO (NASDAQ:RGNX) - Defense World

Nov 19, 2024

Nov 19, 2024

Raymond James maintains $18 target on RGNX after trial data - Investing.com

Nov 19, 2024

Nov 18, 2024

Regenxbio Sets Sights On 2026 Filing For DMD Gene Therapy - Citeline

Nov 18, 2024

Nov 18, 2024

FDA endorses speedy approval path for Regenxbio Duchenne gene therapy - BioPharma Dive

Nov 18, 2024

Nov 18, 2024

Raymond James maintains $18 target on RGNX after trial data By Investing.com - Investing.com UK

Nov 18, 2024

Nov 18, 2024

REGENXBIO (NASDAQ:RGNX) Sees Strong Trading VolumeTime to Buy? - MarketBeat

Nov 18, 2024

Nov 18, 2024

What's Going On With REGENXBIO Shares Monday? - Benzinga

Nov 18, 2024

Nov 18, 2024

Regenxbio Share Surge 20% on Duchenne Muscular Dystrophy Treatment Trial Data, Expansion - MarketWatch

Nov 18, 2024

Nov 18, 2024

Regenxbio (RGNX) Initiates Pivotal Phase Of Affinity Duchenne® Trial Of Rgx-202 Gene Therapy And Reports Positive Functional Data - StreetInsider.com

Nov 18, 2024

Nov 18, 2024

REGENXBIO INITIATES PIVOTAL PHASE OF AFFINITY DUCHENNE® TRIAL OF RGX-202 GENE THERAPY AND REPORTS POSITIVE FUNCTIONAL DATA - PR Newswire

Nov 18, 2024